You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Insulin glulisine

Showing 1 - 25 of 8,063
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Type1 Diabetes Trial in Neuss (Insulin glulisine (U300), Insulin glulisine, Insulin aspart)

Completed
  • Type1 Diabetes Mellitus
  • Insulin glulisine (U300)
  • +6 more
  • Neuss, Germany
    Investigational Site Number 276001
Apr 21, 2022

Type 2 Diabetes Trial in China (INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30)

Completed
  • Type 2 Diabetes Mellitus
  • INSULIN GLARGINE (HOE901)
  • +5 more
  • China, China
    CHINA
Apr 21, 2022

Diabetes, Type 1 Trial in Warsaw (Insulin Glulisine, Insulin Aspart, Insulin Lispro)

Recruiting
  • Diabetes Mellitus, Type 1
  • Insulin Glulisine
  • +2 more
  • Warsaw, Poland
    Department of Pediatric Diabetology and Pediatrics, Pediatric Te
Jan 27, 2022

Type 2 Diabetes Trial in India (INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin)

Completed
  • Type 2 Diabetes Mellitus
  • INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
  • +3 more
  • Bangalore, India
  • +12 more
Apr 21, 2022

Diabetes, Type 1 Diabetes Trial in Atlanta (Rapid-Acting Insulin, Long acting insulin)

Completed
Has Results
  • Diabetes Mellitus
  • Type 1 Diabetes
  • Rapid-Acting Insulin
  • Long acting insulin
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Sep 2, 2021

Type 1 Diabetes Trial in Málaga (Toujeo SoloStar, Tresiba, Humalog Kwikpen)

Completed
  • Type 1 Diabetes Mellitus
  • Toujeo SoloStar
  • +4 more
  • Málaga, Spain
    Regional University Hospital of Málaga
Nov 23, 2021

Down Syndrome Trial in Saint Paul (Insulin glulisine, Saline)

Completed
Has Results
  • Down Syndrome
  • Saint Paul, Minnesota
    HealthPartners Neuroscience Center
Nov 19, 2019

Mild Cognitive Impairment, Alzheimer's Disease (AD) Trial in Minneapolis, Saint Paul (Insulin glulisine, Placebo)

Terminated
Has Results
  • Mild Cognitive Impairment
  • Alzheimer's Disease (AD)
  • Insulin glulisine
  • Placebo
  • Minneapolis, Minnesota
  • +1 more
Apr 8, 2020

Type 1 Diabetes, Lipoatrophy Trial (Apidra, current insulin)

Completed
  • Type 1 Diabetes
  • Lipoatrophy
  • (no location specified)
Oct 18, 2019

Type 2 Diabetes Trial in Gurgaon (Degludec, Glargine U300)

Completed
  • Type 2 Diabetes
  • Gurgaon, Haryana, India
    Division Of Endocrinology and Diabetes , Medanta The Medicity Ho
Mar 3, 2022

Diabetes, Type 1 Trial (Insulin Glulisine, Insulin Aspart, Insulin Lispro)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Insulin Glulisine
  • +2 more
  • (no location specified)
Oct 10, 2019

Diabetes, Diabetes, Type 1, Glucose Metabolism Disorders Trial in Guangzhou (AndroidAPS-rt-CGM;, sensor augmented pump(SAP);)

Recruiting
  • Diabetes Mellitus
  • +6 more
  • AndroidAPS-rt-CGM;
  • sensor augmented pump(SAP);
  • Guangzhou, Guangdong, China
    Jinhua Yan
Feb 12, 2023

Type2 Diabetes Trial in India (Glargine + Glulisine, Premixed analogue insulin (70/30))

Completed
  • Type2 Diabetes
  • Glargine + Glulisine
  • Premixed analogue insulin (70/30)
  • Belgaum, Karnataka, India
  • +7 more
Sep 9, 2019

Type 2 Diabetes Trial in Atlanta, Minneapolis, Cleveland (Glargine U300, Glargine U100, Glulisine Insulin)

Completed
Has Results
  • Type 2 Diabetes
  • Glargine U300
  • +2 more
  • Atlanta, Georgia
  • +3 more
Apr 23, 2020

Type 2 Diabetes, Hyperglycemia Trial in United States (sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus)

Completed
Has Results
  • Type 2 Diabetes
  • Hyperglycemia
  • sliding scale regular insulin (SSRI)
  • +2 more
  • Atlanta, Georgia
  • +4 more
Sep 14, 2018

Type 1 Diabetes Trial in Puerto Rico, United States (HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100

Completed
Has Results
  • Type 1 Diabetes Mellitus
  • HOE901-U300 (Insulin Glargine 300 U/ml)
  • +2 more
  • Little Rock, Arkansas
  • +99 more
Mar 21, 2022

Diabetes (DM) Trial in Cairo (regular insulin, 70/30 insulin, Glargine)

Completed
Has Results
  • Diabetes Mellitus (DM)
  • regular insulin
  • +3 more
  • Cairo, Egypt
    the department of internal medicine, Cairo University teaching h
Jul 17, 2018

Type 2 Diabetes, Type 2 Diabetes Trial in Jacksonville, Macon (VGo)

Completed
Has Results
  • Type 2 Diabetes
  • Type 2 Diabetes Mellitus
  • VGo
  • Jacksonville, Florida
  • +1 more
Feb 10, 2021

Diabetes, Type 1 Trial in United States (Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart)

Completed
Has Results
  • Diabetes Mellitus, Type 1
  • Insulin lispro
  • +4 more
  • Escondido, California
  • +18 more
Feb 5, 2019

Diabetic Ketoacidosis Trial in Atlanta, Minneapolis (insulin glargine+ glulisine, NPH + Regular insulin)

Completed
Has Results
  • Diabetic Ketoacidosis
  • insulin glargine+ glulisine
  • NPH + Regular insulin
  • Atlanta, Georgia
  • +1 more
Aug 30, 2018

Low Fat Meal - Unadjusted Insulin Dose, High Fat Meal - Unadjusted Insulin Dose, High Fat Meal - Adjusted Insulin Dose +30

Completed
  • Low Fat Meal - Unadjusted Insulin Dose
  • +3 more
  • Meal composition
  • Rapid-Acting Insulin Dose
  • (no location specified)
Mar 2, 2021

Type 2 Diabetes Trial in Naples (IDegLira, IGlarLixi, Insulin/Canaglifozin)

Completed
  • Type 2 Diabetes
  • Naples, Italy
    Unit of Endocrinology and Metabolic Diseases
Oct 20, 2020

Type 1 Diabetes Trial in Boston (Multiplex pharmacokinetic profiling, Continuous insulin monitoring)

Completed
Has Results
  • Type 1 Diabetes
  • Multiplex pharmacokinetic profiling
  • Continuous insulin monitoring
  • Boston, Massachusetts
    Massachusetts General Hospital
Nov 21, 2019

Poor Glycemic Control Trial in Atlanta (Metformin, Glargine insulin, Glulisine)

Completed
Has Results
  • Poor Glycemic Control
  • Atlanta, Georgia
  • +2 more
Aug 24, 2018

Central Insulin Resistance, Diabetes, Type 2, PreDiabetes Trial (Human nasal insulin, Placebo)

Not yet recruiting
  • Central Insulin Resistance
  • +2 more
  • Human nasal insulin
  • Placebo
  • (no location specified)
May 12, 2023